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Abstract
Introduction
White matter hyperintensity (WMH) volume on MRI is increased among presymptomatic
individuals with autosomal dominant mutations for Alzheimer’s disease (AD). One potential
explanation is that WMH, conventionally considered a marker of cerebrovascular disease,
are a reflection of cerebral amyloid angiopathy (CAA) and that increased WMH in this popu-
lation is a manifestation of this vascular form of primary AD pathology. We examined
whether the presence of cerebral microbleeds, a marker of CAA, mediates the relationship
between WMH and estimated symptom onset in individuals with and without autosomal
dominant mutations for AD.
Participants and methods
Participants (n = 175, mean age = 41.1 years) included 112 with an AD mutation and 63
first-degree non-carrier controls. We calculated the estimated years from expected symp-
tom onset (EYO) and analyzed baseline MRI data for WMH volume and presence of cere-
bral microbleeds. Mixed effects regression and tests of mediation were used to examine
microbleed and WMH differences between carriers and non-carriers and to test the whether
the association between WMH and mutation status is dependent on the presence of
microbleeds.
Results
Mutation carriers were more likely to have microbleeds than non-carriers (p<0.05) and indi-
viduals with microbleeds had higher WMH volume than those without (p<0.05). Total WMH
volume was increased in mutation carriers compared with non-carriers, up to 20 years prior
to EYO, after controlling for microbleed status, as we demonstrated previously. Formal test-
ing of mediation demonstrated that 21% of the association between mutation status and
WMH was mediated by presence of microbleeds (p = 0.03) but a significant direct effect of
WMH remained (p = 0.02) after controlling for presence of microbleeds.
Discussion
Although there is some co-dependency between WMH and microbleeds, the observed
increases in WMH among mutation carriers does not appear to be fully mediated by this
marker of CAA. The findings highlight the possibility that WMH represent a core feature of
AD independent of vascular forms of beta amyloid.
Introduction
There is an emerging interest in the role of small vessel cerebrovascular changes in late onset
Alzheimer’s disease (AD). While there is general agreement that small vessel cerebrovascular
disease contributes independently to the clinical presentation of AD by lowering clinical diag-
nostic thresholds or conferring additive cognitive impairment, there is considerable controversy
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about whether it plays a primary role in AD pathogenesis, representing a core feature of the dis-
ease. The study of the contribution of small vessel cerebrovascular disease to late onset AD is
difficult because the ordering and timing of the onset of biological changes is obscured by a
potentially decades-long preclinical period[1] and confounded by its strong association with
age and vascular risk factors, such as hypertension. We addressed these issues previously by
turning to the Dominantly Inherited Alzheimer’s Network (DIAN) study[1, 2], which enrolls
individuals at 50% risk for developing AD, typically early onset, by virtue of a having a first-
degree relative with an autosomal dominant, fully-penetrant genetic mutation for AD. We
quantified small vessel cerebrovascular disease as the regional volume of white matter hyperin-
tensities (WMH), areas of increased signal on T2-weighted magnetic resonance imaging (MRI),
that may reflect ischemic injury[3] or other mechanisms. Increased WMH volume, particularly
when distributed in posterior regions, is associated with increased risk for late onset AD and
with the severity and course of the disease[4]. In DIAN, we modeled WMH severity and distri-
bution in mutation carriers and non-carriers as a function of the estimated years to symptom
onset (EYO), defined as the difference between the age of the affected first-degree relative’s age
of symptom onset and the participant’s age[2]. We found that mutation carriers had reliably
increased WMH volume, particularly in posterior regions, which appeared elevated as much as
22 years prior to symptom onset. We concluded that WMH burden is a distinct core feature of
AD that should be considered explicitly in models of disease pathogenesis.
One outstanding issue regarding these findings relates to the presence of cerebral amyloid
angiopathy (CAA), the vascular deposition of amyloid pathology. Cerebral amyloid angiopa-
thy can cause small hemorrhagic lesions, or microbleeds, that manifest as punctate hypoin-
tense voids on gradient echo (GRE) sequences[5]. Previous work showed a relationship of
WMH volume, particularly in posterior areas, with cerebral microbleeds[6] and that individu-
als with familiar forms of AD have comparable frequencies of microbleeds to those with late
onset disease[7, 8]. The question of the extent to which CAA mediates the observed relation-
ship between WMH and AD is critical: if WMH in the context of AD is driven by CAA, then
prevention or intervention strategies could focus on vascular forms of amyloid pathology.
However, if the association of WMH with AD is independent of CAA, then other mechanisms
or forms of vascular pathology (e.g., ischemia, blood brain barrier damage, inflammation-
mediated, etc.) become highly relevant in the conceptualization of disease pathogenesis and
strategies for intervention or prevention. The purpose of this study was to examine the role of
CAA, operationally-defined as the presence of cerebral microbleeds on GRE MRI, in the con-
text of autosomal dominant AD and in the relationship we observed previously between
WMH and autosomal dominant mutation status.
Materials and methods
DIAN study
The Dominantly Inherited Alzheimer’s Network (www.dian-info.org; NIA-U19-AG032438) is
a multisite effort that includes centers in the United States, UK, Germany, Australia, Japan,
Korea, and Argentina. DIAN participants are from families with a known autosomal-domi-
nant mutation for AD, including APP, PSEN1, and PSEN2, irrespective of their own mutation
status. As part of the DIAN, participants receive a baseline assessment with sampling of blood
and CSF, clinical assessment, neuropsychological evaluation, and neuroimaging and are fol-
lowed longitudinally with identical assessments. Full procedures for the study are described
elsewhere[1, 9]. All assessment and imaging procedures were approved by the Washington
University Human Research Protection Office. All participants gave written informed consent
according to the Declaration of Helsinki. Local institutional review boards/ethics committees
White matter hyperintensities and amyloid angiopathy
PLOS ONE | https://doi.org/10.1371/journal.pone.0195838 May 9, 2018 3 / 15
for sites that contributed data to this study include, Columbia University Medical Center Insti-
tutional Review Board; University of Pittsburgh Human Research Protection Office; UCLA
Institutional Review Boards; Indiana University Institutional Review Boards; Partners Human
Research Committee; Butler Hospital Institutional Review Board for Human Subjects
Research; The University of South Wales Human Research Ethics Committee; University of
Melbourne Office for Research Ethics and Integrity; Edith Cowan University Human Research
Ethics Committee; Technical University Munich Institutional Review Board; and University
College London Research Ethics Committee.
Clinical assessment
Clinical assessments were performed by individuals who were unaware of each participant’s
mutation status. The evaluation included neuropsychological testing, medical examination,
administration of the Clinical Dementia Rating (CDR) scale[10], and determination of the
parental age of onset. A semi-structured interview, which determined the age at which the
affected parent started exhibiting symptoms, was used to determine parental age at onset[1, 2].
The difference between the participant’s age and the parental age at onset was used to establish
the EYO. The EYO variable was calculated for all participants regardless of their mutation sta-
tus. Participants with negative EYO are younger than their parental age at onset. Data included
here were a subset from Data Freeze 6.
MRI image processing
Baseline MRI data were analyzed for WMH volume on T2-weighted FLAIR scans (repetition
time: 9,000; echo time: 90; voxel dimensions: 0.86 x 0.86 x 5.0 mm) and for presence and num-
ber of cerebral microbleeds, a radiological marker of CAA, on T2-weighted scans (repetition
time: 650; echo time: 20; voxel dimensions: 0.78 x 0.78 x 5.0 mm). White matter hyperintensity
quantification in this cohort has been described previously[2]. Briefly, an algorithm that
labeled voxel intensity values above a study-specific threshold was applied to each individual
FLAIR image; the number of voxels labeled with this approach were summed and multiplied
by voxel dimensions to yield total WMH volumes for each participants. We also co-registered
a “lobar” atlas to each image to derive the WMH volume in the frontal, temporal, parietal, and
occipital lobes. Because the values were not normally distributed, total and regional WMH vol-
umes were transformed with inverse hyperbolic sine. Fig 1 displays an example of a participant
with prominent posterior WMH.
Microbleeds, sometimes referred to as “microhemorrhages,” were identified on GRE images
following procedures that have been described previously (85% interrater agreement, κ = 68%)
[11]. Briefly, expert operators visually inspected each image and rated microbleeds as homoge-
nous hypointense lesions up to 10 mm in diameter in grey or white matter. We dichotomized
the participants into those with (present) and without (absent) one or more cerebral micro-
bleeds for statistical analyses. Fig 1 displays an example of a cerebral microbleed in a DIAN
participant.
Statistical analysis
SAS (version 9.4) was used for all statistical analyses. Demographic and clinical variables were
compared by microbleed status with Wilcoxson’s test and chi-squared analysis for continuous
and categorical variables, respectively. We also tested whether the difference between those
with and without microbleeds persisted after controlling for EYO and CDR-Sum-of-boxes
(CDR-SB) using linear regression and logistic regressions for continuous and categorical
White matter hyperintensities and amyloid angiopathy
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variables. We used linear mixed-effect regression analysis to test whether WMH volume dif-
fered by mutation type and microbleed status, controlling for participant family as a random
effect.
We also tested whether there is inflection point in microbleed status by the EYO using
piece-wise generalized linear mixed-effect regression. The final models were selected using
Fig 1. Examples of WMH and microbleeds. Left: T2-weighted FLAIR images from a mutation carrier with prominent
posterior WMH, approximately 5 years prior to symptom onset. Right: example of microbleed (arrow) on a gradient echo
MRI scan.
https://doi.org/10.1371/journal.pone.0195838.g001
Fig 2. Mediation models.
https://doi.org/10.1371/journal.pone.0195838.g002
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Bayesian information criteria as described elsewhere[2]. The same inflection point analyses
were carried out for WMH volume with and without microbleed status as a covariate.
Two models described in Fig 2 were tested for the primary hypotheses. Model 1 tested
whether microbleed status is in the causal pathway between mutation status and WMH vol-
ume using mediation analysis. Model 2 tested whether the relationships between mutation sta-
tus, microbleed status, and WMH volume differ by EYO (moderation). We separately tested
whether three paths (between mutation status and WMH, between mutation status and micro-
bleed status, and between microbleed status and WMH) differ by EYO. We did not find signif-
icant moderation effect of EYO on the association between microbleed status and WMH
volume. Thus, in the final model, the moderation effect on the association between microbleed
status and WMH volume was omitted. Based on causal effects models[12–14], the mediation
(or indirect) effect explained by microbleed status was estimated as the difference between the
total effect of mutation status on WMH and direct effect of mutation status on WMH volume
controlling for microbleed status. For statistical inference, bootstrapping was used to derive
95% confidence intervals of the total, direct, and indirect effects. All models were adjusted for
APOE-ε4 status, EYO and age. Models were also re-run with CDR-SB as a covariate and in the
subset of participants with CDR-SB scores of less than or equal to 0.5 (n = 138) and after
excluding individuals with APP mutations (n = 37) because of known associations between
APP and CAA[15].
As a secondary exploratory analysis, we tested the same mediation and moderated-media-
tion of the number of microbleeds on the relationship between mutation status and WMH vol-
ume in the participants with one or more microbleeds (n = 26). The number of microbleeds
was log-transformed to reduce skewness.
Results
Participants
One hundred seventy-five participants had both WMH measures and GRE MRI scans with
derived data of microbleed status. There were 112 mutation carriers of whom 34 (30%) had
CDR-SB scores greater than 1, indicating some degree of manifest symptomatology. There was
a positive association between CDR-SB and EYO (spearman’s correlation ρ = 0.55, p<0.0001)
within the 112 mutation carriers, indicating that CDR-SB scores increased with closer proxim-
ity to the estimated time of symptom onset.
Microbleeds
Data comparing those with and without microbleeds are presented in Table 1. Among the 175
participants, 26 participants (15%) had at least one microbleed. Thirteen of 26 participants
(50%) had one microbleed, 12 participants had 2–29 microbleeds and one participant had 135
microbleeds. Individuals with microbleeds were 4.6 years older, 4.5 years closer to the esti-
mated age of onset, and had 1.61 points higher CDR-SB scores than the 146 participants with-
out microbleeds. These 26 participants had a more severe biomarker profile than those
without, including increased total WMH and WMH volume in temporal, parietal, and occipi-
tal lobes, and decreased CSF Aβ1–42, and CSF Aβ1-42/tau ratio values. These differences per-
sisted after controlling for EYO and CDR-SB, except for the difference in CSF Aβ1-42/tau
ratio values. Mutation carriers were more likely to have microbleeds than non-carriers (19.6%
vs. 6.3%, Fisher’s exact test p = 0.025). This association remained significant (OR = 4.87, 95%
CI: 1.16,20.51; p = 0.0334) after adjustment for age, EYO and APOE-ε4 status. Age and
APOE- ε4 status were not associated with microbleed status (all p’s >0.15).
White matter hyperintensities and amyloid angiopathy
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We also tested whether the proportion of individuals with microbleeds varied as a function
of EYO (i.e., an inflection point). Based on Bayesian information criteria, we did not find evi-
dence of an inflection point in microbleed frequency; the difference in frequency of micro-
bleed status between mutation carriers and non-carriers as a function of EYO was not
significant (p = 0.36), although mutation carriers more likely have microbleeds than non-carri-
ers (p = 0.02). The distribution of the microbleed status by EYO group is found in S1 Table.
White matter hyperintensity volume
In this sub-sample of individuals with available microbleed data, we found a similar pattern of
differences in WMH volume between mutation carriers and non-carriers as we reported previ-
ously[2]: mutation carriers had elevated total and regional WMH, which appeared to diverge
approximately 20 years prior to EYO. This pattern remained even after controlling for micro-
bleed status. Presence of microbleeds was associated with increased regional and total WMH
volume (Table 2).
Mediation analysis
Individuals with microbleeds had higher total and regional, including temporal, parietal, and
occipital WMH volumes than those without microbleeds (Table 1, Fig 3). The 95% confidence
intervals of total, direct, and indirect effects were estimated from 1,000 bootstrapped samples.
We found that the higher total WMH volume among mutation carriers (total effect,
p = 0.0009) was not significantly mediated by microbleed status (indirect effect, p = 0.1389)
Table 1. Demographic, clinical, and biomarker data in microbleed presence and absence.
All (n = 175) Microbleed Absent
(n = 149)
Microbleed Present (n = 26) p-value
Mutation Carriers, n (%)

112 (64.00) 90 (60.4) 22 (84.62) 0.0252
Age, mean years±SD

41.05 ±9.66 40.36 ±9.43 45.00 ±10.19 0.0234
EYO, mean years±SD

-5.14 ±9.32 -5.81 ±9.29 -1.31 ±8.70 0.0227
Women, n (%) 100 (57.14) 87 (58.39) 13 (50) 0.5204
Vascular factors (%) Hypertension 20 (11.43) 15 (10.07) 5 (19.23) 0.1854
Hypercholesterolemia 27 (15.61) 21 (14.29) 6 (23.08) 0.2508
Diabetes 2 (1.14) 1 (0.67) 1 (3.85) 0.2758
Smoke 73 (41.71) 65 (43.62) 8 (30.77) 0.2826
CDR-SB±SD

1.03 ±2.31 0.79 ±2.15 2.40 ±2.77 0.0009
APOE-ε4+, n (%) 55 (31.43) 49 (32.89) 6 (23.08) 0.3685
WMH, mean IHS±SD Frontal 0.20 0.47 0.15 ±0.25 0.49 ±1.03 0.1065
Temporal 0.08 0.29 0.04 ±0.12 0.32 ±0.65 0.0370
Parietal 0.16 0.53 0.08 ±0.22 0.60 ±1.19 0.0357
Occipital 0.23 0.42 0.18 ±0.29 0.54 ±0.78 0.0261
Total 0.59 0.79 0.49 ±0.57 1.13 ±1.44 0.0338
CSF Aβ1–42
a, 328.94 153.50 349.5 ±148.31 196.74 ±118.68 <.0001
CSF ptau181b 57.55 38.94 55.2 ±38.78 71.9 ±37.73 0.0752
CSF Aβ1–42:tau ratio
a, 5.42 4.98 5.91 ±5.09 2.32 ±2.61 <.0001
aAvailable for n = 141.
bAvailable for n = 144.
p<0.05;
p<0.001
https://doi.org/10.1371/journal.pone.0195838.t001
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although it explained approximately 20% of the total effect. Similar patterns were found for the
regional WMH volumes (see Table 3). The effect of mutation was moderated by EYO (total
effect of EYOMutation: p’s<0.05) except for frontal WMH, which had trend level significance
(p = 0.05), but there was no significant moderated mediation (indirect effect of EYOMuta-
tion, p’s>0.29) (Table 4). These findings persist even after controlling for CDR-SB (S2 Table).
Similar results were found in the subset of CDR-SB is less and equal than 0.5 (S3 Table) and
after excluding APP participants (S4 Table).
Table 2. Mixed effect regression coefficients for total and regional WMH volumes and CSF biomarkers.
Outcome Effect Estimate S.E. DF t Value p-value
Frontal lobe WMH volume Intercept -0.082 0.24 79 -0.34 0.7342
Mutation, Carriers 0.153 0.083 89 1.84 0.0688
Microbleed present

0.299 0.099 89 3.01 0.0034
EYO -0.007 0.007 89 -0.99 0.3255
EYO Mutation 0.009 0.007 89 1.24 0.2181
AGE 0.003 0.005 89 0.56 0.58
APOE-ε4, Positive 0.064 0.074 89 0.86 0.3925
Temporal lobe WMH volume Intercept -0.177 0.148 79 -1.2 0.2354
Mutation, Carriers 0.097 0.049 89 1.98 0.0507
Microbleed present

0.241 0.059 89 4.09 <.0001
EYO -0.004 0.004 89 -0.89 0.3733
EYO Mutation 0.006 0.004 89 1.28 0.2044
AGE 0.004 0.003 89 1.17 0.2434
APOE-ε4, Positive -0.021 0.044 89 -0.47 0.6372
Parietal lobe WMH volume Intercept -0.243 0.268 79 -0.91 0.3669
Mutation, Carriers

0.197 0.09 89 2.18 0.0319
Microbleed present

0.448 0.108 89 4.14 <.0001
EYO -0.004 0.007 89 -0.5 0.62
EYO Mutation 0.009 0.008 89 1.08 0.281
AGE 0.005 0.006 89 0.84 0.4051
APOE-ε4, Positive 0.012 0.081 89 0.15 0.8792
Occipital lobe WMH volume Intercept -0.119 0.22 79 -0.54 0.5884
Mutation, Carriers

0.223 0.072 89 3.08 0.0027
Microbleed present

0.28 0.087 89 3.23 0.0017
EYO -0.004 0.006 89 -0.68 0.4992
EYO Mutation 0.011 0.006 89 1.68 0.0974
AGE 0.004 0.005 89 0.81 0.4186
APOE-ε4, Positive -0.001 0.066 89 -0.01 0.9904
Total WMH volume Intercept 0.127 0.418 79 0.3 0.762
Mutation, Carriers

0.421 0.136 89 3.08 0.0027
Microbleed present

0.507 0.164 89 3.09 0.0027
EYO -0.012 0.012 89 -1.08 0.2833
EYO Mutation

0.028 0.012 89 2.3 0.0236
AGE 0.002 0.009 89 0.27 0.785
APOE-ε4, Positive 0.02 0.124 89 0.16 0.8707
p<0.05;
 p<0.01;
p<0.001
https://doi.org/10.1371/journal.pone.0195838.t002
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Finally, when we limited analyses to those individuals with microbleeds (n = 26) and tested
whether the number of microbleeds mediated the relationship between mutation status and
regional or global WMH volume, we did not find evidence of a mediational relationship
(p’s> 0.63).
Discussion
Several important observations emerged from this work among individuals with and without
genetic mutations for AD. First, the primary aim of this study was to determine the extent to
which the increased WMH among mutation carriers reflects, or is mediated by, increases in
vascular forms of beta amyloid, which we operationally defined as presence of cerebral micro-
bleeds. Although we observed some co-dependency between WMH and cerebral microbleeds,
the increased WMH volume among mutation carriers was only modestly mediated by this
marker of cerebral amyloid angiopathy. Second, those with microbleeds had more severe AD
fluid biomarker profiles, defined as lower levels of CSF Aβ42 and lower CSF Aβ42/tau ratios.
Third, individuals with mutations were more likely to have cerebral microbleeds than those
without mutations, although this increased likelihood did not vary as a function of estimated
time to symptom onset, perhaps due to a relatively small sample size (S4 Table). Finally, we
were able to reproduce our previous finding[2] of increased WMH volume among mutation
Fig 3. Total and regional WMH volume by microbleed status. Total and regional WMH volumes are expressed in inverse hyperbolic sine
transformation units. Individuals with microbleeds had significantly greater total WMH volumes and WMH volumes in temporal, parietal,
and occipital lobes.
https://doi.org/10.1371/journal.pone.0195838.g003
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carriers up to 20 years prior to expected symptom onset in this subset of participants with
available GRE scans.
There is considerable debate about the role of cerebrovascular disease in AD onset and
pathogenesis. Current pathogenic models of the disease[16] and their application to clinical
diagnostic criteria[17–19] emphasize a single pathway that begins with fibrillar forms of
(parenchymal) beta amyloid, followed by the deposition of tau pathology, which subsequently
results in neurodegeneration and clinical symptoms. But there is ample evidence of involve-
ment of cerebrovascular disease in AD. Postmortem studies consistently demonstrate that the
presence of cerebrovascular lesions among symptomatic individuals with AD is much more
common than not and suggest that pathologies, including cerebrovascular disease, in addition
to primary AD pathology, lower the threshold, increase risk, or are perhaps necessary for the
disease to express clinically[20]. In vivo neuroimaging studies support a similar conclusion: up
to one third of older adults with no apparent symptomatology have evidence of amyloid depo-
sition sufficient enough to meet pathological criteria for AD[21], but increased markers of
cerebrovascular disease seem to distinguish symptomatic individuals with amyloidosis from
asymptomatic individuals with amyloidosis[22]. A common interpretation of such findings is
that cerebrovascular disease represents a comorbidity that lowers the clinical diagnostic
threshold for AD and contributes additively to disease presentation. The opportunity to test
the extent to which cerebrovascular disease is playing a role among individuals with autosomal
dominant genetic mutations for AD offers the unique opportunity to test the extent to which
cerebrovascular disease is a “core” feature of AD; the work here, combined with our previous
observation[2], provides evidence that WMH are not merely a comorbidity or confounding
factor but rather reflect primary pathological features of the disease, present in individuals
genetically-determined to develop the disease. Participants in this study were all of equal likeli-
hood of inheriting an autosomal dominant mutation for AD and were essentially “randomly
Table 3. Mediation analysis results without the estimate years of onset adjusted.
Effect Estimate S.E. 95% CI z p-value
Total WMHI Volume total  0.3896 0.1172 0.1634 0.6304 3.3248 0.0009
direct  0.3126 0.1116 0.0894 0.5256 2.8011 0.0051
indirect 0.077 0.0521 -0.0057 0.1974 1.4797 0.1389
Frontal Lobe total  0.1069 0.0484 0.0113 0.2092 2.2075 0.0273
direct 0.0774 0.043 -0.0048 0.1654 1.7998 0.0719
indirect 0.0295 0.0243 -0.0056 0.0842 1.214 0.2247
Temporal Lobe total  0.1067 0.0405 0.038 0.1963 2.6351 0.0084
direct  0.0746 0.0321 0.0199 0.1487 2.3238 0.0201
indirect 0.032 0.0238 -0.0032 0.0867 1.3486 0.1775
Parietal Lobe total  0.2207 0.074 0.0937 0.3846 2.9843 0.0028
direct  0.158 0.0562 0.064 0.2833 2.8118 0.0049
indirect 0.0628 0.044 -0.0045 0.163 1.4259 0.1539
Occipital Lobe total  0.2378 0.0643 0.12 0.3801 3.6973 0.0002
direct  0.1965 0.0606 0.0871 0.3248 3.2438 0.0012
indirect 0.0413 0.0265 -0.0013 0.1051 1.5599 0.1188
p<0.05;
p<0.01;
p<0.001;
All models were adjusted for APOE-4 and age.
https://doi.org/10.1371/journal.pone.0195838.t003
White matter hyperintensities and amyloid angiopathy
PLOS ONE | https://doi.org/10.1371/journal.pone.0195838 May 9, 2018 10 / 15
assigned” to the carrier or non-carrier groups, thus providing experimental evidence for
increased WMH in genetically-determined AD.
White matter hyperintensities are typically considered markers of small vessel cerebrovas-
cular disease and postmortem correlates studies suggest several changes secondary to ischemic
injury, including demyelination, axonal loss, blood barrier dysfunction, and arteriolosclerosis
[3]. Because of the high levels of amyloidosis among individuals with autosomal mutations for
AD[1], the extent to which WMH reflects CAA is a possibility that motivated the current
study. There is understandably little information about pathological changes in the white mat-
ter of individuals with autosomal dominant forms of AD, considering the low prevalence of
individuals with autosomal forms of AD. In one study, WMH volume determined in vivo did
Table 4. Covariate adjusted total, indirect and direct effects of mutation status. APOE-4 and age were adjusted in all the models. The 95% confidence intervals of
total, direct and indirect effect were estimated from 1000 bootstrapped samples.
Effect Estimate S.E. 95% CI z p-value
Total WMH volume total EYOMutation  0.0313 0.0105 0.0113 0.0526 2.9924 0.0028
Mutation  0.5541 0.1438 0.2862 0.8461 3.8529 0.0001
direct EYO Mutation  0.028 0.0107 0.0073 0.0492 2.6129 0.009
Mutation  0.4672 0.1392 0.1883 0.7449 3.356 0.0008
indirect EYO Mutation 0.0033 0.0036 -0.0024 0.0117 0.9217 0.3567
Mutation 0.0869 0.0615 -0.013 0.2269 1.414 0.1574
Frontal Lobe total EYO Mutation 0.0105 0.0054 -0.0003 0.0211 1.9463 0.0516
Mutation  0.1615 0.0625 0.0321 0.289 2.5852 0.0097
direct EYO Mutation 0.0093 0.0052 -0.0013 0.0196 1.7901 0.0734
Mutation  0.1271 0.0551 0.0161 0.2345 2.3081 0.021
indirect EYO Mutation 0.0012 0.0018 -0.0016 0.006 0.6843 0.4938
Mutation 0.0344 0.0285 -0.0082 0.1009 1.2081 0.227
Temporal Lobe total EYO Mutation  0.0089 0.0036 0.0024 0.0172 2.4608 0.0139
Mutation  0.1546 0.0532 0.0667 0.2708 2.9074 0.0036
direct EYO Mutation 0.0076 0.0037 0.001 0.0159 2.0257 0.0428
Mutation  0.1167 0.044 0.0447 0.2141 2.6532 0.008
indirect EYO Mutation 0.0014 0.0019 -0.0016 0.0055 0.74 0.4593
Mutation 0.0379 0.0288 -0.0041 0.1036 1.3172 0.1878
Parietal Lobe total EYO Mutation  0.0132 0.0061 0.0022 0.0261 2.1683 0.0301
Mutation  0.291 0.0957 0.1232 0.4993 3.0405 0.0024
direct EYO Mutation 0.0097 0.006 -0.0014 0.023 1.6174 0.1058
Mutation  0.2121 0.0735 0.0913 0.3714 2.8841 0.0039
indirect EYO Mutation 0.0035 0.0033 -0.0022 0.0114 1.0586 0.2898
Mutation 0.0789 0.0536 -0.0045 0.2017 1.4711 0.1413
Occipital Lobe total EYO Mutation  0.0132 0.0055 0.0027 0.0239 2.4168 0.0157
Mutation  0.308 0.0757 0.1683 0.4728 4.0668 <0.0001
direct EYO Mutation  0.0113 0.0057 0.0005 0.0221 1.987 0.0469
Mutation  0.2602 0.0728 0.1246 0.4212 3.5762 0.0003
indirect EYO Mutation 0.0019 0.0018 -0.0008 0.0062 1.0218 0.3069
Mutation 0.0477 0.0316 -0.0045 0.1216 1.5093 0.1312
p<0.05;
p<0.01;
p<0.001;
All models were adjusted for APOE-4 and age.
https://doi.org/10.1371/journal.pone.0195838.t004
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correlate modestly with CAA restricted to the temporal lobes, but also correlated with lepto-
meningeal blood vessel diameter and lower density of CD68-positive microglia in posterior
brain regions, where the impact of WMH is greatest[2, 4]. The findings here also suggest that
the increased observed WMH in autosomal dominant AD is not attributable entirely to CAA.
It is important to note that among autosomal dominant mutation carriers for AD, the patho-
physiological basis of WMH has not been elucidated clearly, and could include damage due to
ischemia, as is observed in aging, or to other factors such as blood brain barrier dysfunction,
Wallerian-like degeneration secondary to neurodegeneration, and inflammation. Thus, we
speculate that the role of WMH in autosomal dominant AD reflects either the primary involve-
ment of vascular damage in AD or the manifestation of other pernicious factors, such as
inflammation, in AD. Indeed, a recent study showed some preliminary evidence of increased
T-lymphocytic responses in the postmortem white matter tissue of PSEN1 mutation carriers
[23]. Nonetheless, our results suggest that both radiological phenomena—- microbleeds and
WMH—- are important features of AD. Future work should therefore consider more explicitly
the underlying mechanisms as potential drivers of disease pathogenesis and treatment targets
as opposed to comorbidities not central to the disease.
Cerebral microbleeds in the current study were measured on GRE 3T MRI scans. These
scans are known to have good specificity for microbleed detection but relatively lower sensitiv-
ity compared with susceptibility weighted images and higher field strength magnets. Relatively
few microbleeds were detected and it is possible that some participants had microbleeds that
were undetected by the technology employed, thus somewhat biasing our analyses towards the
null hypothesis and producing Type II statistical errors. On the other hand, the high specificity
of microbleed detection on GRE gives us confidence that individuals identified as having
microbleeds were accurately classified and have evidence of the presence of CAA. When we
restricted the sample to only those participants with detectable microbleeds, we also did not
find a mediating role of CAA in the relationship between mutation status and WMH volume,
which supports our overall observation, although relatively low sample size could also bias the
findings somewhat towards the null. Furthermore, microbleeds that distributed in subcortical/
deep regions are typically attributed to hypertensive pathology whereas microbleeds distrib-
uted in lobar regions are typically attributed to CAA. Not surprising for the age and population
under study, microbleeds in the current sample tended to be in lobar regions. Only two partic-
ipants had exclusively deep microbleeds. We re-ran the analyses coding these individuals has
having microbleed status of “absent” and the results remained essentially unchanged (data not
shown).
The development of disease modifying interventions for AD has resulted in a number of
disappointing results[24]. Recent trials that focused on treatments that attempt to clear fibrillar
amyloid pathology or prevent its deposition yielded negative findings with respect to clinical
outcomes and removal of amyloid, despite some moderate evidence of target engagement[24].
There has been little focus on vascular mechanisms as feasible targets for treatment of preven-
tion strategies. This work adds to a growing body of literature that clearly implicates WMH in
AD; future work should consider mechanisms of WMH including cerebrovascular disease and
interventions that focus on cerebrovascular disease in AD.
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